PDGF Side Effects: What Studies Report

What "PDGF" refers to in the published literature

Platelet-derived growth factor (PDGF) is a family of signalling proteins — PDGF-A, PDGF-B, PDGF-C and PDGF-D, which assemble into dimers such as PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD — acting through the receptors PDGFR-α and PDGFR-β. When published papers discuss PDGF, they are usually working in one of three distinct settings:

• Endogenous PDGF biology in animal or cell models, where researchers manipulate a ligand or receptor and describe what changes in tissue.
• PDGF-receptor inhibition, where multikinase drugs that block PDGFR (among other targets) are given to patients in oncology trials, and adverse events are tabulated.
• Platelet-derived preparations such as platelet-rich plasma (PRP) or plasma rich in growth factors (PRGF), which contain PDGF alongside dozens of other proteins.

These three settings produce very different observations, and the literature does not treat them as interchangeable. A safety signal generated by blocking a receptor is not the mirror image of giving the ligand, and an adverse event recorded after an autologous blood-derived injection cannot be attributed to PDGF specifically. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment.

Human safety data on administered PDGF: a stated absence

The papers summarised here do not include a controlled human trial in which isolated PDGF or a PDGF-mimetic peptide was administered to volunteers or patients with adverse events systematically collected and graded. There is, in this evidence set, no published human adverse-event profile, no dose-ranging safety data, and no long-term follow-up for exogenous PDGF administration. That absence is the honest answer to the question of "PDGF side effects" in humans: the primary data required to answer it have not been reported in the literature reviewed here.

Recombinant PDGF proteins, PDGFR-targeting peptides and PDGF-containing nanocarriers described in these papers functioned as research reagents in laboratory and animal work. Research-use-only materials are not evaluated for human safety, and their laboratory use does not generate the kind of dataset — treatment-emergent adverse events, discontinuation rates, laboratory abnormalities — that clinical safety questions require. Readers looking for the underlying biology rather than the safety literature can work through the PDGF course at /learn/pdgf/, which covers receptor signalling and study design; this page stays with what has been observed and reported about harms.

Preclinical signals: what animal and tissue studies observed

Kidney inflammation

In a 2025 experimental study, researchers reported that platelet-derived growth factor-C contributed to kidney inflammation in experimental hypertension while having little effect on the peritubular capillary network (PMID 40882295). The study is a mechanistic animal model, not a safety study, but it is one of the clearer illustrations in this set that a PDGF ligand can be associated with an inflammatory rather than a purely regenerative tissue response.

Pulmonary vasculature

A 2025 paper in Pulmonary Circulation explored the impact of platelet-derived growth factor D on pulmonary hypertension development, placing a PDGF family member inside the pathogenesis of a vascular remodelling disease rather than its treatment (PMID 41323293). Because pulmonary vascular remodelling involves smooth-muscle and fibroblast proliferation — cell types that respond to PDGF — this line of work is frequently cited as a theoretical concern when discussing systemic PDGF activity, though the reported experiments addressed disease mechanism, not administered-peptide safety.

Fibrosis and activated stellate cells

A 2025 drug-delivery study used PDGFR-β-targeting peptide-modified chitosan nanoparticles to carry anti-TGF-β1 siRNA to fibrotic liver tissue, and researchers reported reduced fibrosis in their experimental model (PMID 41014631). The relevant point for a safety discussion is why PDGFR-β works as an address label: the receptor is upregulated on activated hepatic stellate cells, the cells that drive fibrosis. In other words, PDGFR-β expression is used in the literature as a marker of fibrogenic activation.

Bone and joint remodelling

A 2022 study in Bone Research reported that prostaglandin E2 acting through EP4 receptors on subchondral bone osteoclasts regulated osteoarthritis progression (PMID 35260562). That work sits in the same compartment — subchondral bone remodelling and aberrant angiogenesis — that growth-factor signalling studies frequently examine, and it illustrates how tightly regulated local remodelling is in joint tissue.

Ocular angiogenesis

A 2024 review of therapeutic options for corneal neovascularization catalogued anti-angiogenic strategies used to suppress new vessel growth in the cornea, reflecting that pro-angiogenic signalling in that tissue is treated as pathology to be reversed (PMID 38791518). PDGF is a pro-angiogenic and pericyte-recruiting family, so the direction of therapeutic effort in the eye is informative about context-dependence: the same biology that is desirable in a healing wound is undesirable in a clear cornea.

A reported beneficial effect, also preclinical

Not every PDGF finding is a harm signal. In a 2025 eLife study, researchers reported therapeutic effects of PDGF-AB/BB against cellular senescence in human intervertebral disc tissue (PMID 40668091). That work used human-derived cells and tissue rather than living patients, so it describes a biological effect under laboratory conditions and did not generate clinical adverse-event data.

What PDGFR-inhibitor trials show — and what they do not

The largest body of human data touching the PDGF pathway comes from oncology drugs that block multiple receptor kinases including PDGFR. In the phase 3 REFLECT trial of first-line treatment for unresectable hepatocellular carcinoma, the most common any-grade adverse events reported with lenvatinib were hypertension (42%), diarrhoea (39%), decreased appetite (34%) and decreased weight (31%), while sorafenib was associated with palmar-plantar erythrodysaesthesia (52%), diarrhoea (46%), hypertension (30%) and decreased appetite (27%) (PMID 29433850). In that trial lenvatinib was given at 12 mg or 8 mg daily by body weight and sorafenib at 400 mg twice daily, with median overall survival of 13.6 months versus 12.3 months (PMID 29433850).

Those numbers are frequently mis-borrowed into discussions of "PDGF side effects." They should not be. They describe the toxicity of small-molecule inhibitors that hit VEGFR, FGFR, PDGFR, RET and KIT simultaneously at systemic doses in patients with advanced liver cancer — a pharmacology unrelated to giving a growth-factor ligand. A 2025 preclinical study in the same disease area reported that proteoglycan-4 potentiated the antitumour efficacy of regorafenib, another multikinase inhibitor, in an orthotopic hepatocellular carcinoma model (PMID 41327374). What this inhibitor literature does establish is that the PDGF axis is considered a growth-promoting pathway worth blocking in tumour biology — which is why the absence of human data on ligand administration matters.

Platelet-derived preparations: the nearest clinical context

Because platelets are a major PDGF reservoir, PRP and PRGF studies are often read as proxies. The literature cautions against that reading. A 2017 review of platelet-derived therapies in alopecia described the range of preparation protocols in use and the state of the evidence base (PMID 29270414). A 2025 narrative review of platelet-rich plasma therapy for tendon injuries of the hand similarly reported that the available evidence remained limited and heterogeneous (PMID 41306375).

Composition is not fixed either. A 2024 study reported that inflammatory skin conditions altered the biological profile of plasma rich in growth factors obtained from affected individuals (PMID 39299031). If the growth-factor content of an autologous preparation varies with the donor's inflammatory state, then adverse events recorded after such injections cannot be assigned to any single constituent, PDGF included.

Reported signals at a glance

Why the gaps are large

Several structural features of this literature limit what can be said about harms:

1. Model-to-human distance. Kidney, lung and disc findings came from animal models or human tissue preparations, not from people receiving a compound (PMID 40882295, PMID 40668091).
2. Direction of intervention. Most human PDGF-pathway data come from inhibition, not administration (PMID 29433850).
3. Attribution problem. Platelet-derived injections deliver mixtures whose composition varies between donors and conditions (PMID 39299031).
4. Context dependence. The same pro-angiogenic activity sought in repair is targeted for suppression in the cornea (PMID 38791518).

Closing those gaps would require prospective human studies with defined preparations, predefined adverse-event collection, and follow-up long enough to capture fibrotic, vascular and proliferative outcomes. No such dataset appears in the papers summarised here. Until it exists, statements about the safety of administered PDGF in humans are extrapolations from mechanism rather than findings, and the literature should be read as describing biology, not establishing a harm profile. This page is educational only and does not constitute medical advice.

References

• Platelet-derived growth factor-C contributes to kidney inflammation in experimental hypertension with little effect on the peritubular capillary network (Experimental and Molecular Pathology, 2025)
• Exploring the Impact of Platelet-Derived Growth Factor D in Pulmonary Hypertension Development (Pulmonary Circulation, 2025)
• Therapeutic effects of PDGF-AB/BB against cellular senescence in human intervertebral disc (eLife, 2025)
• Targeted Delivery of Anti-TGF-β(1)-siRNA Using PDGFR-β Peptide-Modified Chitosan Nanoparticles for the Treatment of Liver Fibrosis (Molecular Pharmaceutics, 2025)
• PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis (Bone Research, 2022)
• Available Therapeutic Options for Corneal Neovascularization: A Review (International Journal of Molecular Sciences, 2024)
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (Lancet, 2018)
• Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma (Journal of Experimental & Clinical Cancer Research, 2025)
• Alopecia and platelet-derived therapies (Stem Cell Investigation, 2017)
• Platelet-Rich Plasma Therapy in Treating Tendon Injuries of the Hand: A Narrative Review (Orthopedic Reviews, 2025)
• Impact of inflammatory skin conditions on the biological profile of plasma rich in growth factor (Tissue & Cell, 2024)